Literature DB >> 7665590

Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides.

S M Fennewald1, R F Rando.   

Abstract

Oligonucleotides can be used to inhibit the binding of basic fibroblast growth factor to cells. Though standard phosphodiester oligonucleotides show a slight inhibition of binding, the oligonucleotides with phosphorothioate internucleoside linkages have inhibition levels equivalent to that of the polyanion heparin. Variations in sequence of the oligonucleotides does lead to differences in the inhibitory action of the oligonucleotides. This inhibition of basic fibroblast growth factor by phosphorothioate oligonucleotides may account for much of the published data on inhibition of various genes by proposed antisense oligonucleotides and needs to be taken into account when considering the mechanism of action of oligonucleotides in biological systems.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7665590     DOI: 10.1074/jbc.270.37.21718

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  The experimental use of antisense oligonucleotides: a guide for the perplexed.

Authors:  C A Stein
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

2.  The high binding affinity of phosphorothioate-modified oligomers for Ff gene 5 protein is moderated by the addition of C-5 propyne or 2'-O-methyl modifications.

Authors:  Tung-Chung Mou; Donald M Gray
Journal:  Nucleic Acids Res       Date:  2002-02-01       Impact factor: 16.971

3.  Direct comparison of the specificity of gene silencing using antisense oligonucleotides and RNAi.

Authors:  Benoit Bilanges; David Stokoe
Journal:  Biochem J       Date:  2005-06-01       Impact factor: 3.857

4.  Antisense Oligonucleotides: Treatment Strategies and Cellular Internalization.

Authors:  Colton M Miller; Edward N Harris
Journal:  RNA Dis       Date:  2016-08-15

5.  Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes.

Authors:  Clément Guillot; Nora Martel; Françoise Berby; Isabelle Bordes; Olivier Hantz; Matthieu Blanchet; Camille Sureau; Andrew Vaillant; Isabelle Chemin
Journal:  PLoS One       Date:  2017-06-21       Impact factor: 3.240

Review 6.  The future of antisense oligonucleotides in the treatment of respiratory diseases.

Authors:  Marina Ulanova; Alan D Schreiber; A Dean Befus
Journal:  BioDrugs       Date:  2006       Impact factor: 5.807

7.  Heparan sulfate proteoglycans present PCSK9 to the LDL receptor.

Authors:  Camilla Gustafsen; Ditte Olsen; Joachim Vilstrup; Signe Lund; Anika Reinhardt; Niels Wellner; Torben Larsen; Christian B F Andersen; Kathrin Weyer; Jin-Ping Li; Peter H Seeberger; Søren Thirup; Peder Madsen; Simon Glerup
Journal:  Nat Commun       Date:  2017-09-11       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.